Ligand Pharma (LGND) Tops Q4 EPS by 49c
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $298.93 +0.14%
EPS Growth %: -24.9%
Financial Fact:
Net income (loss):: 1.05M
Today's EPS Names:
OCCI, ALZN, ASPU, More
EPS Growth %: -24.9%
Financial Fact:
Net income (loss):: 1.05M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Ligand Pharma (NASDAQ: LGND) reported Q4 EPS of $1.36, $0.49 better than the analyst estimate of $0.87. Revenue for the quarter came in at $50.38 million versus the consensus estimate of $44.09 million.
For earnings history and earnings-related data on Ligand Pharma (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Paychex (PAYX) Tops Q1 EPS by 2c
- Ligand Acquires Royalty and Milestone Interest in Santen’s Ryjunea® from Sydnexis for $23 Million
- Primrose Bio® Raises Significant Growth Capital Investment Led by Signet Healthcare Partners
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
